Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
  • Patent number: 10526394
    Abstract: The invention relates, firstly, to a biomolecule-releasing cell characterised by a surface protein with an extracellularly exposed ligation peptide sequence for enzymatic conjugation of an adapter ligand, said adapter ligand being suitable for the indirect or direct coupling of a molecular catcher structure which has at least one specific binding site for the released biomolecules and which is at a distance from the specific binding site, secondly, to a method for selecting such a cell, and thirdly, to a means for this method comprising the surface protein that is characterised by an extracellularly exposable ligation peptide sequence for enzymatic conjugation of an adapter ligand, a nucleic acid coding for the surface protein, an expression vector for the nucleic acid, and a cell containing the expression vector.
    Type: Grant
    Filed: April 20, 2014
    Date of Patent: January 7, 2020
    Assignee: NEW / ERA / MABS GMBH
    Inventors: Martin Listek, Katja Hanack, Burkhard Micheel
  • Patent number: 9241989
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: January 26, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
  • Publication number: 20150135341
    Abstract: Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the cells for animal models of hyperproliferative disorders including metastatic cancer, diagnostic methods, and therapeutic methods are provided.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 14, 2015
    Applicant: GENESYS RESEARCH INSTITUTE
    Inventor: Lynn Hlatky
  • Publication number: 20150132286
    Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 14, 2015
    Inventors: Bruno DOMON, Ian MCCAFFREY, Vaibhav NARAYAN, Scott PATTERSON
  • Publication number: 20150113669
    Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: September 25, 2014
    Publication date: April 23, 2015
    Inventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang
  • Patent number: 8999707
    Abstract: This invention relates to a novel hybridoma strategy that uses CD27+ B cells cultured in vitro to induce IgM to IgG class switch prior to fusion with a fusion partner. Hybridomas resulting from the fusion between CD27+ B cells and a fusion partner cell line and antibodies secreted from the hybridomas are included in the invention.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: April 7, 2015
    Assignee: Thomas Jefferson University
    Inventors: Scott K. Dessain, Sharad P. Adekar
  • Patent number: 8993319
    Abstract: The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: March 31, 2015
    Assignees: Innate Pharma S.A., University of Genova
    Inventors: Alessandro Moretta, Emanuela Marcenaro, Francois Romagne, Pascale Andre
  • Patent number: 8981063
    Abstract: The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors. Also included are methods of making and using these co-stimulatory polypeptides.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: March 17, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Lieping Chen
  • Publication number: 20150064787
    Abstract: The present invention is directed generally to host cells with artificial endosymbionts, wherein the artificial endosymbiont and the host cell communicate with each other to alter a phenotype of the host cell. In some embodiments, the communication comprises the secretion of a polypeptide from the artificial endosymbiont into the host cell. The secreted polypeptide can be a selectable marker, a reporter protein, a transcription factor, a signal pathway protein, a receptor, a growth factor, a cytokine, an effector molecule or other factors that can produce a phenotype in the host cell.
    Type: Application
    Filed: September 3, 2014
    Publication date: March 5, 2015
    Inventors: Caleb B. Bell, III, Alexey Bazarov, Abdul Wakeel, Joyce Barrozo
  • Patent number: 8968740
    Abstract: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 3, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Fundacion Sales
    Inventors: Margaret A. Shipp, Jing Ouyang, Kunihiko Takeyama, Jeffery L. Kutok, Scott J. Rodig, Gabriel Rabinovich, Diego Omar Croci Russo, Mariana Salatino
  • Patent number: 8969531
    Abstract: The present invention discloses a method for assaying the binding of L104EA29YIg to a receptor. The receptor is preferably CD86 or CD80. The present invention also discloses antibodies to be used in the assay, as well as hybridomas expressing the antibodies.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: March 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventor: Francisco Leon
  • Patent number: 8945867
    Abstract: The present invention relates to a process for producing a desired polypeptide using rat cells. Specifically, the present invention relates to a process for producing the polypeptide which comprises culturing rat cells such as YB2/3HL.P2.G11.16Ag.20 (hereinafter referred to as YB2/0), preferably rat cells to which a recombinant DNA comprising DNA encoding a desired polypeptide such as an immunologically functional molecule is introduced, in a medium which does not contain serum (hereinafter referred to as a serum-free medium). Among the desired polypeptides obtained by the process of the present invention, an antibody obtained by using a transformant of YB2/0 has a high antibody-dependent cell-mediated cytotoxic activity (hereinafter sometimes referred to as ADCC activity) and is useful as a pharmaceutical agent.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Tatsuya Ogawa, Yoshinobu Konno, Naohisa Akashi, Hiroshi Takasugi, Seiji Sugimoto, Keiichi Yano
  • Publication number: 20150024485
    Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).
    Type: Application
    Filed: September 10, 2014
    Publication date: January 22, 2015
    Inventors: MICHEL KOBR, PHILIPPE DUPRAZ
  • Publication number: 20150004689
    Abstract: Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Disclosure of a method to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Disclosure of a method to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment administering the patient-specific cell line to the patient.
    Type: Application
    Filed: September 12, 2014
    Publication date: January 1, 2015
    Inventor: Thiru Venkat Gopal
  • Publication number: 20140377407
    Abstract: This invention relates to a novel alpha-amylase, a process for its preparation and the use of the amylase. The invention relates to a newly identified polynucleotide sequence from Alicyclobacillus pohliae comprising a gene that encodes the novel alpha-amylase enzyme. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein of the gene. The invention also relates to methods of using these proteins in industrial processes, for example in food industry, such as the baking industry. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins and cells.
    Type: Application
    Filed: January 29, 2013
    Publication date: December 25, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventor: Lucie Parenicova
  • Publication number: 20140329312
    Abstract: The present invention a method for producing a human immunoglobulin G (IgG) antibody using a prime-boost regime in a Bone Marrow Liver Thymic (BLT) mouse.
    Type: Application
    Filed: November 26, 2012
    Publication date: November 6, 2014
    Inventors: William G. North, Steven N. Fiering
  • Publication number: 20140308257
    Abstract: The present invention provides modified oocytes having a nuclear genome derived from a first oocyte and cytoplasm derived from a second oocyte from a different subject, and methods for making and using such modified oocytes. The methods and compositions of the present invention can be useful in a variety of settings including, but not limited to, in in vitro fertilization (“IVF”) procedures.
    Type: Application
    Filed: December 5, 2013
    Publication date: October 16, 2014
    Applicant: New York Stem Cell Foundation
    Inventor: Dietrich M. Egli
  • Patent number: 8859278
    Abstract: Certain aspects of the present invention are directed to new fully human fusion partner cell lines called human Karyochi cells, and to methods for making them. Human Karyochi cells are then fused with human antibody-secreting lymphoid cells to make fully human hybridomas called Karyochi-based hybridomas, which likewise secrete fully human monoclonal antibodies. Human Karyochi cells are made by isolating a donor nucleus that is substantially free of cytoplasm from either a first malignant B-lymphocyte cell line or a normal B-lymphocyte, and transferring the donor nucleus into the cytoplasm of a recipient cell from a second T- or B-lymphoid cell line. With time the nuclei synchronize and fuse to form the chimeric Karyochi fusion partner cell line. Nuclear transfer can be accomplished using intra-cytosolic nucleus injection or by impact-induced nucleus administration.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: October 14, 2014
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ilya Trakht, Gavreel Kalantarov
  • Patent number: 8846028
    Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: September 30, 2014
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Lowell L. Wood, Jr.
  • Publication number: 20140273203
    Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
    Type: Application
    Filed: September 23, 2013
    Publication date: September 18, 2014
    Applicant: Bell Biosystems, Inc.
    Inventors: Caleb B. Bell, III, Alexey Bazarov
  • Publication number: 20140248700
    Abstract: An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.
    Type: Application
    Filed: May 7, 2014
    Publication date: September 4, 2014
    Applicant: Advanced Cell Technolgy
    Inventors: Jose Cibelli, Michael West, Robert Lanza
  • Publication number: 20140248316
    Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Applicant: Orbis Health Solutions LLC
    Inventors: Thomas E. Wagner, Yanzhang Wei
  • Patent number: 8809508
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: August 19, 2014
    Assignee: Probiodrug AG
    Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
  • Patent number: 8785186
    Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.
    Type: Grant
    Filed: August 24, 2009
    Date of Patent: July 22, 2014
    Assignee: Orbis Health Solutions LLC
    Inventors: Thomas E. Wagner, Yanzhang Wei
  • Publication number: 20140201858
    Abstract: The invention relates to organisms and compositions comprising one or more stem cells or one or more embryos, wherein the one or more stem cells or one or more embryos comprise one or more of the following mutations: (i) a deletion mutation; (ii) a knockout mutation; and/or (iii) an addition of a heterologous nucleic acid sequence; wherein the one or more mutations of (i), (ii), and/or (iii) are site-specific mutations caused by a Xanthomonas TAL nuclease (XTN). The invention also relates to method of mutating an embryo, iPS cell, stem cell, or more particularly a spermatogonial stem cell by exposing the nucleic acid sequence contained within such embryos or cell with a Xanthomonas TAL nuclease.
    Type: Application
    Filed: May 17, 2012
    Publication date: July 17, 2014
    Applicant: Transposagen Biopharmaceuticals, Inc
    Inventors: Eric M. Ostertag, John S. Crawford, J. Keith Joung
  • Patent number: 8778361
    Abstract: The present invention provides a dendritic cell-based vaccine by fusing a canine tumor cell and an allogeneic dendritic cell, and a method for preparing the same. The fusion cells expressing canine tumor antigens are generated by fusing canine bone marrow-derived dendritic cells and canine tumor cells. The canine immune system can be induced to produce tumor specific T lymphocytes and natural killer cells when the fusion cells used as a vaccine is injected into a canine body.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: July 15, 2014
    Assignee: National Taiwan University
    Inventors: Rea-Min Chu, Chien-Chun Pai, Tien-Fu Chuang
  • Patent number: 8778677
    Abstract: The present invention relates to hybrid cells and methods for producing hybrid cells. In particular, the invention relates to hybrid cells generated from the hybridization of at least three cells where at least two cells are derived from different lineages. The invention further relates to the use of hybrid cells for the expression of proteins useful in a range of diagnostic, prophylactic, therapeutic and/or research applications.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: July 15, 2014
    Assignee: BTS Research International PTY. Ltd.
    Inventors: Galina Kaseko, Tohsak L. Mahaworasilpa
  • Publication number: 20140170180
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Application
    Filed: March 12, 2013
    Publication date: June 19, 2014
    Applicant: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA, Callie Ann VISEK
  • Publication number: 20140162296
    Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.
    Type: Application
    Filed: March 14, 2013
    Publication date: June 12, 2014
    Inventors: Katherine E. Varley, Richard M. Myers, Brian S. Roberts, Jason Gertz, Donald J. Buchsbaum, Andres Forero-Torres, Albert F. LoBuglio
  • Publication number: 20140154800
    Abstract: An embryonic stem cell line derived from a nucleus-transferred oocyte prepared by transferring a nucleus of a human somatic cell into an enucleated human oocyte may differentiate into various desired cell types.
    Type: Application
    Filed: November 26, 2013
    Publication date: June 5, 2014
    Applicant: H. Bion Co., Ltd.
    Inventors: Sung-Il ROH, Woo-Suk HWANG, Byeong-Chun LEE, Sung-Keun KANG, Young-June RYU, Eu-Gene LEE, Soon-Woong KIM, Dae-Kee KWON, Hee-Sun KWON, Ja-Min KOO, Eul-Soon PARK, Youn-Young HWANG, Hyun-SOO YOON, Jong-Hyuk PARK, Sun-Jong KIM
  • Patent number: 8722401
    Abstract: A method for the in vitro production of a cell population P? from a cell population P, the production requiring the presence of at least one factor which is expressed by feeder cells, wherein a) feeder cells proliferate at a temperature T1, b) proliferated feeder cells are contacted with the cell population P, c) the cell mixture obtained at step (b) is cultivated at a temperature T2 which is chosen such that the cell population P proliferates and the feeder cells do not proliferate, the at least one factor being expressed by the feeder cells, and d) the cell population P? so produced is recovered. Advantageously, the production consists in an expansion, the feeder cells are insect feeder cells and the cell population P to be expanded is a T lymphocyte population, preferably a Trl lymphocyte population.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: May 13, 2014
    Assignees: TxCell, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Hervé Groux, Françoise Cottrez, Hervé Bastian, Valérie Brun
  • Patent number: 8715683
    Abstract: Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: May 6, 2014
    Assignee: Immunex Corporation
    Inventor: Dirk M Anderson
  • Patent number: 8679835
    Abstract: Provided herein are an isolated or enriched population of tumor initiating cells derived from normal cells, cells susceptible to neoplasia, or neoplastic cells. Methods of use of the cells for screening for anti-hyperproliferative agents, and use of the cells for animal models of hyperproliferative disorders including metastatic cancer, diagnostic methods, and therapeutic methods are provided.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: March 25, 2014
    Assignee: GeneSys Research Institute
    Inventor: Lynn Hlatky
  • Publication number: 20140073019
    Abstract: The present invention relates to the field of biotransformation of furanic compounds. More particular the present invention relates to novel genetically modified cells with improved characteristics for biocatalytic transformation of furanic compounds and a vector suitable for the genetic modification of a host cell. Further aspects of the invention are aimed at processes for biotransformation of 5-(hydroxymethyl)furan-2-carboxylic acid (HMF-acid) and its precursors with the use of the cell according to the invention.
    Type: Application
    Filed: March 7, 2012
    Publication date: March 13, 2014
    Applicant: PURAC BIOCHEM B.V.
    Inventors: Nick Johannes Petrus Werckx, Tom Daniel Elink Schuurman, Sipko Maarten Kuijper, Harald Johan Ruijssenaars
  • Patent number: 8669351
    Abstract: Canavan disease, an autosomal recessive leukodystrophy, is caused by deficiency of aspartoacylase and accumulation of N-acetylaspartic acid in brain. Human aspartoacylase (ASP) cDNA spanning 1,435 bp has been cloned and expressed in E. coli. A base change, a854>c, has been found in 85% of the 34 Canavan alleles tested so far, which results in a missense glu285>ala mutation that is predicted to be part of the catalytic domain of aspartoacylase. The invention therefore provides nucleic acid sequences, genes, polypeptides, antibodies, vectors containing the gene, host cells transformed with vectors containing the gene, animal models for the disease, methods for expressing the polypeptide, genetic screening methods and kits, diagnostic methods and kits, methods of treating Canavan disease and methods of genetic therapy for the disease.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: March 11, 2014
    Assignee: Miami Children's Hospital
    Inventors: Reuben Matalon, Rajinder Kaul, Guang Ping Cao, Kuppareddi Balamurugan, Kimberlee Michals-Matalon
  • Publication number: 20140050661
    Abstract: The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to the 414H5 and 515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered.
    Type: Application
    Filed: September 13, 2013
    Publication date: February 20, 2014
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Christine KLINGUER-HAMOUR, Alexandra Jouhanneaud, Veronique Grenier-Caussanel
  • Publication number: 20140053288
    Abstract: The present invention relates to a model animal spontaneously developing anemia. More specifically, the invention relates to a transgenic non-human mammal spontaneously developing anemia associated with a postnatal decrease in production of erythropoietin (Epo), Epo-producing cells prepared from the transgenic non-human mammal, and a screening method using the Epo-producing cells.
    Type: Application
    Filed: March 29, 2012
    Publication date: February 20, 2014
    Applicant: TOHOKU TECHNO ARCH CO., LTD.
    Inventors: Masayuki Yamamoto, Naoko Minegishi, Shun Yamazaki
  • Patent number: 8652472
    Abstract: An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount.
    Type: Grant
    Filed: December 5, 2007
    Date of Patent: February 18, 2014
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: John Lewicki, Austin Gurney, Sanjeev Satyal
  • Publication number: 20140038210
    Abstract: Herein are reported a monoclonal antibody specifically binding to a human IgG1 antibody and not specifically binding to the immunoglobulin of an experimental animal and the use of the antibody in immunoassays.
    Type: Application
    Filed: February 15, 2013
    Publication date: February 6, 2014
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130309651
    Abstract: The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 21, 2013
    Applicant: INGURAN, LLC
    Inventors: Richard Lenz, Juan Moreno, Ramakrishnan Vishwanath
  • Patent number: 8557575
    Abstract: This invention relates to a novel fusion partner cell line that ectopically expresses IL-6 and TERT termed B5-6T, and to methods for making the B5-6T fusion partner cell line. The B5-6T fusion partner cell line can be fused with B-lymphocytes to generate hybridomas that secrete human monoclonal antibodies.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: October 15, 2013
    Assignee: Thomas Jefferson University
    Inventors: Scott K. Dessain, Sharad P. Adekar
  • Patent number: 8546542
    Abstract: The invention relates to an antibody that inhibits histamine releasing activity induced by an antigenic substance contained in sweat. The invention further relates to an antibody which can react with a sweat antigen composition and inhibit the histamine releasing activity of the composition on a sweat antigen stimulation-responsive cell.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: October 1, 2013
    Assignee: Hiroshima University
    Inventors: Michihiro Hide, Toshihiko Tanaka, Kaori Ishii, Hidenori Suzuki
  • Publication number: 20130230917
    Abstract: This invention relates to the culture of dendritic cells from human embryonic stem (ES) cells. Human ES cells are first cultured into hematopoietic cells by co-culture with stromal cells. The cells now differentiated into the hematopoietic lineage are then cultured with GM-CSF to create a culture of myeloid precursor cells. Culture of the myeloid precursor cells with the cytokines GM-CSF and IL-4 causes functional dendritic cells to be generated. The dendritic cells have a unique phenotype, as indicated by their combination of cell surface markers.
    Type: Application
    Filed: April 9, 2013
    Publication date: September 5, 2013
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Igor I. Slukvin, James A. Thomson, Maksym A. Vodyanyk, Maryna E. Gumenyuk
  • Publication number: 20130225422
    Abstract: Disclosed herein is a system and method for making allele calls, and for determining the ploidy state, in one or a small set of cells, or where a limited quantity of genetic data is available. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed and the haplotypes are determined using expected similarities between the target genome and the knowledge of the genomes of genetically related individuals. In one embodiment, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the genetic data from both parents, and possibly one or more sperm and/or sibling embryos. In another embodiment, the chromosome copy number can be determined using the same input data. In another embodiment, these determinations are made for embryo selection during IVF, for non-invasive prenatal diagnosis, or for making phenotypic predictions.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 29, 2013
    Applicant: Natera, Inc.
    Inventors: Matthew Rabinowitz, George Gemelos, Milena Banjevic, Allison Ryan, Joshua Sweetkind-Singer
  • Publication number: 20130203113
    Abstract: There is provided a method to increase the production of a desired protein in a microorganism by introduction of slowly translated codons in the encoding DNA gene sequence capable of slowing down the translation speed of the ribosomes moving along the mRNA, whereby the ribosomes protect the mRNA from being enzymatically degraded. This increases the stability of the mRNA transcript and thus results in an increased production of the desired protein. Moreover, there is provided a method of decreasing the half-life of a mRNA transcript from a gene encoding a peptide.
    Type: Application
    Filed: May 5, 2011
    Publication date: August 8, 2013
    Applicant: Kobenhavns Universitet
    Inventors: Steen Pedersen, Kim Sneppen, Margit Pedersen, Sine Lo Svenningsen, Namiko Mitarai
  • Publication number: 20130196429
    Abstract: This invention discloses a substantially protein-free cell culture solution for assisted reproductive technologies and methods of use thereof.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 1, 2013
    Inventor: Jaffar Ali bin M. Abudallah
  • Publication number: 20130183758
    Abstract: The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
    Type: Application
    Filed: January 13, 2012
    Publication date: July 18, 2013
    Applicant: Bell Biosystems, Inc.
    Inventors: Caleb B. Bell, III, Alexey V. Bazarov
  • Publication number: 20130184185
    Abstract: The present invention relates to methods for increasing the diversity of monoclonal antibodies produced against an antigen. The methods of the invention utilize immunization of a murine host defective in one or more enzymes involved in a post-translational modification of a polypeptide or a modification of a lipid, wherein said modification is exposed on a cell surface. The invention also relates to monoclonal antibodies produced by these methods and which are not produced when a normal mouse is immunized with the same antigen. The invention further relates to compositions comprising these monoclonal antibodies, as well as to such monoclonal antibodies bound or conjugated to a toxin, a detectable marker or to a solid support.
    Type: Application
    Filed: March 4, 2013
    Publication date: July 18, 2013
    Applicant: ACTON BIOTECH CONSULTING
    Inventor: ACTON BIOTECH CONSULTING
  • Publication number: 20130183299
    Abstract: Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample.
    Type: Application
    Filed: March 13, 2013
    Publication date: July 18, 2013
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventor: EISAI R&D MANAGEMENT CO., LTD.
  • Publication number: 20130171714
    Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).
    Type: Application
    Filed: January 16, 2013
    Publication date: July 4, 2013
    Applicant: MERCK SERONO SA
    Inventor: MERCK SERONO SA